Phospho-ATR (S428) Antibody

What is the biological function of ATR and its S428 phosphorylation site?

ATR (Ataxia Telangiectasia and Rad3-related) is a serine/threonine kinase that functions as a critical DNA damage sensor. It activates checkpoint signaling upon genotoxic stresses including ionizing radiation, ultraviolet light, and DNA replication stalling. Phosphorylation at S428 has been identified in mass spectrometry studies of ATR from cells treated with DNA-damaging agents . The S428 site is located outside the FAT (FRAP, ATM, TRRAP) domain, unlike the functionally characterized T1989 phosphorylation site which plays a crucial role in ATR activation .

While the specific functional significance of S428 phosphorylation remains less characterized than other sites like T1989, experiments testing an ATR S428A mutant demonstrated that this phosphorylation site is not critical for Chk1 activation, unlike the T1989 site which is essential for ATR checkpoint function .

How does ATR contribute to DNA damage response pathways?

ATR functions through multiple mechanisms within DNA damage response pathways:

• Checkpoint Activation: ATR recognizes the substrate consensus sequence [ST]-Q and phosphorylates multiple downstream targets .

• Substrate Phosphorylation: ATR phosphorylates BRCA1, CHEK1, MCM2, RAD17, RBBP8, RPA2, SMC1, and p53/TP53, which collectively:

  • Inhibit DNA replication

  • Prevent premature mitotic entry

  • Promote DNA repair mechanisms

  • Facilitate recombination processes

  • Trigger apoptosis when necessary

• Histone Modification: ATR phosphorylates histone variant H2AX at Ser-139 at DNA damage sites .

• Cell Cycle Regulation: Acts as a regulator of the S-G2 transition by restricting CDK1 activity during S-phase .

What techniques can be used to detect phosphorylated ATR at S428?

Multiple validated techniques can be employed to detect phosphorylated ATR at S428:

Each technique requires specific sample preparation and optimization for reliable phospho-ATR detection.

How should I design experiments to investigate ATR activation in response to different DNA damage agents?

When studying ATR activation through S428 phosphorylation in response to different DNA damage agents, consider this experimental approach:

• Treatment Selection: Include diverse DNA damage inducers to observe different ATR activation patterns:

  • UV irradiation: Induces direct DNA damage and crosslinking

  • Ionizing radiation: Causes double-strand breaks

  • Hydroxyurea (HU): Depletes nucleotide pools and stalls replication forks

  • Nocodazole: Disrupts microtubules leading to mitotic arrest

• Time Course Analysis: Conduct kinetic studies to capture the temporal dynamics of S428 phosphorylation:

  • Short-term effects: 15-30 minutes post-treatment

  • Long-term effects: 20+ hours (for agents like Nocodazole)

• Controls:

  • Untreated cells as negative control

  • Phosphatase treatment of cell extracts to validate phospho-specificity

  • Comparison with other ATR phosphorylation sites (e.g., T1989)

• Detection Methods: Implement multiple complementary techniques from section 1.3 to validate findings.

How can I validate the specificity of a phospho-ATR (S428) antibody for my research?

Ensuring antibody specificity is critical for reliable research outcomes. A comprehensive validation strategy includes:

• Phospho-specificity Testing:

  • Compare detection in untreated vs. DNA damage-induced samples

  • Treat sample aliquots with lambda phosphatase to eliminate phosphorylation signal

  • Use phospho-blocking peptides specific to the S428 site

• Genetic Validation:

  • Express wild-type ATR vs. ATR S428A mutant (serine to alanine) in cells

  • Confirm absence of antibody detection with the S428A mutant

• Technical Controls:

  • Include positive control samples (e.g., UV-treated 293T, NIH/3T3, or C6 cells)

  • Use recombinant protein with/without in vitro phosphorylation as standards

  • Examine multiple relevant cell lines to confirm consistent detection

• Signal Validation:

  • Verify the observed molecular weight matches the expected 300-301 kDa

  • Assess subcellular localization (chromosome, nucleus, PML body)

What are the key considerations when interpreting contradictory phospho-ATR (S428) data across different experimental conditions?

When facing contradictory data regarding phospho-ATR (S428), consider these analytical approaches:

• Technical Variables:

  • Antibody clonality effects: Compare results from polyclonal (pAb) vs. monoclonal (mAb) antibodies

  • Fixation and extraction methods: Certain buffers may affect phospho-epitope detection

  • Antigen retrieval procedures: High-pressure antigen retrieval with citrate buffer may be necessary for IHC applications

• Biological Confounders:

  • Cell cycle phase: ATR phosphorylation status may vary across cell cycle stages

  • Cell type-specific regulation: Different cell lines may exhibit distinct ATR phosphorylation patterns

  • Cross-talk with other phosphorylation sites: T1989 phosphorylation may influence S428 detection

• Temporal Dynamics:

  • ATR phosphorylation events may follow specific sequences after DNA damage

  • Transient vs. sustained phosphorylation patterns require appropriate time-course analysis

• Functional Context:

  • S428 phosphorylation may not correlate directly with ATR kinase activity, unlike T1989

  • Consider analyzing downstream ATR substrates (e.g., Chk1) in parallel to assess functional outcomes

Western Blot Protocol:

• Sample Preparation:

  • Lyse cells in buffer containing phosphatase inhibitors (1 mM NaF, 1 mM Na₃VO₄) to preserve phosphorylation

  • Include 50 mM glycerophosphate and protease inhibitors in lysis buffer

  • Use 25 μg of total protein per lane for optimal detection

• Immunoblotting:

  • Transfer proteins to membranes using standard protocols

  • Block with 5% BSA (preferred over milk for phospho-epitopes)

  • Incubate with primary antibody (1:500 dilution recommended for initial testing)

  • Use HRP-conjugated anti-rabbit secondary antibody (1:10000 dilution)

  • Visualize using enhanced chemiluminescence

• Validation Controls:

  • Include UV-treated cells as positive control

  • Consider Nocodazole-treated samples (50 ng/ml at 37°C for 20 hours) as alternative control

Immunofluorescence Protocol:

• Cell Preparation:

  • Culture cells on coverslips or chamber slides

  • Apply appropriate DNA damage treatment (e.g., UV)

  • Fix cells with 4% paraformaldehyde

• Staining:

  • Permeabilize with 0.1% Triton X-100

  • Block with 5% normal serum

  • Incubate with phospho-ATR (S428) antibody (1:100 dilution)

  • Counterstain with DAPI for nuclear visualization

  • Apply appropriate fluorescent secondary antibody

• Analysis:

  • Examine nuclear localization of phospho-ATR signal

  • Compare signal intensity between treated and untreated samples

How can I optimize immunohistochemical detection of phospho-ATR (S428) in tissue sections?

Successful IHC detection of phospho-ATR (S428) requires careful optimization:

• Tissue Preparation:

  • Use freshly fixed tissues when possible

  • For paraffin-embedded tissues, perform high-pressure antigen retrieval with 0.01M citrate buffer (pH 6.0)

  • Consider section thickness (4-6 μm recommended)

• Staining Protocol:

  • Deparaffinize and rehydrate sections using standard protocols

  • Apply antigen retrieval as described above

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with appropriate serum

  • Incubate with phospho-ATR (S428) antibody at 1:100 dilution

  • Apply secondary antibody and develop signal according to detection system

• Tissue Selection:

  • Testis tissue has been validated for phospho-ATR (S428) detection in mouse and rat samples

  • Include tissues with known DNA damage/repair activity as positive controls

• Signal Evaluation:

  • Use 40x magnification for detailed examination

  • Assess nuclear localization pattern

  • Compare with negative controls (primary antibody omitted)

What approaches can address challenging detection of phospho-ATR (S428) in samples with low expression levels?

When working with samples exhibiting low phospho-ATR (S428) levels:

• Signal Amplification Strategies:

  • Implement tyramide signal amplification (TSA) for IHC/IF applications

  • Use high-sensitivity ECL substrates for Western blot

  • Consider biotin-streptavidin amplification systems

• Sample Enrichment Methods:

  • Perform immunoprecipitation with total ATR antibody followed by phospho-ATR detection

  • Use the TGN buffer system (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM phosphoglycerol, 10% glycerol, 1% Tween 20) with phosphatase inhibitors for efficient extraction

  • Enrich for nuclear fractions where ATR predominantly localizes

• Induction Approaches:

  • Maximize phosphorylation signal by optimizing DNA damage treatment

  • Consider synchronized cell populations to capture peak phosphorylation windows

  • Test multiple DNA-damaging agents to identify optimal induction conditions

• Technical Optimization:

  • Reduce antibody dilution (e.g., 1:50 for IHC/IF)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize secondary antibody concentration and detection systems

How does phosphorylation at S428 compare with other ATR phosphorylation sites in terms of function and regulation?

The phosphorylation landscape of ATR includes multiple sites with distinct functions:

Research has demonstrated that among these sites, T1989 plays a crucial role as a molecular switch:

• T1989 phosphorylation is recognized by TopBP1 via BRCT domains 7 and 8

• This interaction enables TopBP1 to engage ATR-ATRIP, stimulate ATR kinase activity, and facilitate substrate recognition

• T1989A mutation severely impairs checkpoint activation, while T1989D (phosphomimetic) restores function

In contrast, S428A mutation does not impair Chk1 activation, suggesting this site may have other functions distinct from the core checkpoint activation mechanism .

What is the relationship between ATR S428 phosphorylation and downstream signaling events in the DNA damage response?

The relationship between S428 phosphorylation and downstream signaling involves:

• Integration with ATR Activation Mechanisms:

  • While S428 phosphorylation occurs after DNA damage, the core ATR activation depends on:

    • RPA-coated single-stranded DNA recognition

    • ATRIP-mediated recruitment to damage sites

    • TopBP1 interaction (primarily through T1989 phosphorylation)

    • Autophosphorylation events in trans

• Downstream Substrate Phosphorylation:

  • Activated ATR phosphorylates multiple substrates at [S/T]-Q motifs:

    • Chk1 (critical for checkpoint activation)

    • BRCA1 (facilitates DNA repair)

    • RAD17 and RPA2 (stabilize stalled replication forks)

    • p53 and SMC1 (regulate cell cycle progression and apoptosis)

• Cellular Outcome Regulation:

  • ATR signaling orchestrates multiple responses:

    • Cell cycle arrest at G1/S and G2/M transitions

    • Protection of replication fork stability

    • DNA repair pathway activation

    • Apoptosis when damage is irreparable

Given that S428A mutation does not impair Chk1 activation, S428 phosphorylation may be involved in regulating alternative ATR functions or interact with non-canonical pathways distinct from the core checkpoint response .

How can phospho-ATR (S428) antibodies be incorporated into multi-parameter analyses of DNA damage response pathways?

Integrating phospho-ATR (S428) detection into comprehensive DNA damage response analyses:

• Co-detection Strategies:

  • Multiplex immunofluorescence combining phospho-ATR (S428) with:

    • γ-H2AX (Ser139) for DNA damage sites

    • Phospho-Chk1 (Ser345) for ATR activity

    • RPA32 (phospho-S4/S8) for ssDNA-binding protein recruitment

    • BRCA1 (phospho-S1524) for homologous recombination pathway

• Sequential Analysis Workflow:

  • First tier: Detect initial damage using γ-H2AX

  • Second tier: Assess checkpoint activation via phospho-ATR (S428) and phospho-ATM (Ser1981)

  • Third tier: Evaluate downstream effectors (Chk1, Chk2, p53)

  • Fourth tier: Monitor repair pathway choice (BRCA1, 53BP1, Rad51)

• Multi-omics Integration:

  • Combine phospho-ATR antibody-based analyses with:

    • Phosphoproteomics to identify global phosphorylation changes

    • Transcriptomics to assess gene expression responses

    • DNA damage assays (comet, TUNEL) to measure damage resolution

• High-content Imaging Applications:

  • Develop automated image analysis workflows for:

    • Nuclear phospho-ATR (S428) foci quantification

    • Co-localization with other DNA damage response factors

    • Single-cell analysis of response heterogeneity

    • Temporal dynamics throughout DNA damage response

This multi-parameter approach provides a comprehensive view of ATR's role within the broader DNA damage response network and cellular outcomes.

What are the most common technical challenges when working with phospho-ATR (S428) antibodies and how can they be resolved?

How should researchers validate experimental findings based on phospho-ATR (S428) antibody detection?

A robust validation framework includes:

• Technical Validation:

  • Reproduce findings with different antibody clones/sources

  • Apply at least two independent detection methods (e.g., WB and IF)

  • Include appropriate positive and negative controls in each experiment

• Biological Validation:

  • Perform genetic manipulation (siRNA/CRISPR) of ATR to confirm specificity

  • Use ATR kinase inhibitors to assess phosphorylation dependency

  • Introduce S428A mutation to verify antibody specificity

• Functional Correlation:

  • Correlate S428 phosphorylation with ATR kinase activity assays

  • Assess downstream substrate phosphorylation (e.g., Chk1)

  • Examine cellular outcomes (cell cycle arrest, DNA repair, apoptosis)

• Reproducibility Measures:

  • Conduct experiments with biological replicates

  • Quantify results using appropriate statistical methods

  • Document detailed protocols including antibody lot numbers

What quality control measures should be implemented when establishing phospho-ATR (S428) antibody-based assays in a new research laboratory?

Establishing reliable phospho-ATR (S428) detection requires:

• Antibody Qualification:

  • Test multiple commercial antibodies to identify optimal performer

  • Validate each new lot with positive control samples

  • Compare recombinant monoclonal vs. polyclonal antibodies for consistency

• Assay Optimization:

  • Determine optimal antibody concentration through titration experiments

  • Establish standard curves using control samples with known phosphorylation status

  • Develop detailed standard operating procedures (SOPs)

• System Suitability Tests:

  • Include positive controls (UV-treated cells) in each experiment

  • Run phosphatase-treated negative controls

  • Implement internal reference standards for quantitative applications

• Documentation and Training:

  • Create detailed protocols with critical parameters highlighted

  • Implement researcher training and competency assessment

  • Establish criteria for successful/failed experiments

• Long-term Monitoring:

  • Track antibody performance over time and across lots

  • Monitor signal-to-noise ratios and detection limits

  • Periodically revalidate assays with positive control samples

How might advanced technologies enhance the study of ATR S428 phosphorylation in DNA damage response research?

Emerging technologies offer new opportunities for ATR phosphorylation research:

• Super-resolution Microscopy:

  • STORM/PALM imaging to visualize nanoscale organization of phospho-ATR within damage sites

  • Live-cell super-resolution to track real-time phosphorylation dynamics

• Proximity Labeling Technologies:

  • BioID or TurboID fused to ATR to identify proteins interacting specifically with phosphorylated ATR

  • Spatially-resolved proteomic mapping of phospho-ATR interaction networks

• Single-cell Analysis:

  • Mass cytometry (CyTOF) for multi-parameter profiling of phospho-ATR alongside other DDR components

  • Single-cell phosphoproteomics to capture heterogeneity in ATR activation

• CRISPR-based Technologies:

  • Base editing to introduce specific phospho-site mutations (S428A/D)

  • Optogenetic control of ATR activation to study temporal dynamics

• Structural Biology Approaches:

  • Cryo-EM of ATR complexes to understand conformational changes associated with S428 phosphorylation

  • Hydrogen-deuterium exchange mass spectrometry to map phosphorylation-induced structural alterations

What are the potential clinical applications for phospho-ATR (S428) detection in cancer research and treatment?

Phospho-ATR (S428) detection has several potential clinical applications:

• Biomarker Development:

  • Diagnostic marker for DNA damage response defects in tumors

  • Predictive biomarker for response to:

    • ATR inhibitors (currently in clinical trials)

    • PARP inhibitors (synthetic lethality)

    • Platinum-based chemotherapies

    • Radiation therapy

• Therapeutic Target Engagement:

  • Pharmacodynamic marker to confirm ATR inhibitor activity in vivo

  • Tool for determining optimal dosing and scheduling of DNA-damaging therapies

• Resistance Mechanism Identification:

  • Monitor changes in ATR phosphorylation status during treatment

  • Identify adaptive responses that contribute to therapy resistance

• Personalized Medicine Applications:

  • Stratify patients based on tumor phospho-ATR status

  • Guide combination therapy decisions based on ATR activation patterns

  • Monitor treatment response through sequential biopsies

These applications could enhance precision medicine approaches for cancers with DNA repair defects.

How might the understanding of ATR S428 phosphorylation contribute to broader research on cellular stress responses beyond DNA damage?

ATR S428 phosphorylation research has implications beyond canonical DNA damage responses:

• Integration with Other Stress Response Pathways:

  • Cross-talk between DNA damage and:

    • Replication stress responses

    • Oxidative stress pathways

    • Metabolic stress sensing

    • Mechanical stress signaling

• Cell Fate Determination Mechanisms:

  • Role in balancing survival vs. apoptotic outcomes

  • Contribution to cellular senescence programs

  • Influence on stem cell maintenance and differentiation

• Developmental and Physiological Contexts:

  • Function during embryonic development and tissue homeostasis

  • Role in aging-associated DNA damage accumulation

  • Contribution to neurodegenerative conditions

• Emerging Non-canonical Functions:

  • Potential roles in:

    • RNA processing and stability

    • Protein synthesis regulation

    • Organelle stress responses

    • Immune signaling pathways